SK Biopharmaceuticals, fresh off an FDA nod, preps for $850M IPO in January: report

Right on the heels of an FDA approval for seizure med Xcopri, South Korea’s SK Biopharmaceuticals is reportedly planning an initial public offering to raise about $850 million.